AR056245A1 - Membranas virales reconstituidas funcionales que contienen un coadyuvante - Google Patents
Membranas virales reconstituidas funcionales que contienen un coadyuvanteInfo
- Publication number
- AR056245A1 AR056245A1 ARP040102097A ARP040102097A AR056245A1 AR 056245 A1 AR056245 A1 AR 056245A1 AR P040102097 A ARP040102097 A AR P040102097A AR P040102097 A ARP040102097 A AR P040102097A AR 056245 A1 AR056245 A1 AR 056245A1
- Authority
- AR
- Argentina
- Prior art keywords
- coadyuvant
- membranes
- viral membranes
- membranes containing
- reconstituted viral
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000034217 membrane fusion Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Vacunas dirigidas contra antígenos, tales como las proteínas de membrana de patogenos o células tumorales. Método para formar membranas virales reconstruidos, con actividad de fusion de membranas, que son membranas con dos capas de lípidos que contienen preferiblemente lípidos naturales de un virus, una proteína de fusion viral, uno o más antígenos adicionales opcionales, así como coadyuvantes anfifílicos, como por ejemplo lipopéptidos, glicolípidos o péptidos, entre otros. Las composiciones farmacéuticas que comprenden dichas membranas virales reconstruidas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL0300450 | 2003-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056245A1 true AR056245A1 (es) | 2007-10-03 |
Family
ID=33550371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102097A AR056245A1 (es) | 2003-06-19 | 2004-06-16 | Membranas virales reconstituidas funcionales que contienen un coadyuvante |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7618641B2 (es) |
| EP (2) | EP2368576B1 (es) |
| JP (1) | JP4685005B2 (es) |
| KR (1) | KR101225199B1 (es) |
| CN (1) | CN100556454C (es) |
| AR (1) | AR056245A1 (es) |
| AU (1) | AU2004246974B2 (es) |
| BR (1) | BRPI0411519A (es) |
| CA (1) | CA2527735C (es) |
| DK (2) | DK1633395T3 (es) |
| ES (2) | ES2536689T3 (es) |
| IL (1) | IL172584A (es) |
| MX (1) | MXPA05013929A (es) |
| NO (1) | NO20055934L (es) |
| PL (2) | PL1633395T3 (es) |
| RU (1) | RU2348428C2 (es) |
| TW (1) | TWI329130B (es) |
| UA (1) | UA87269C2 (es) |
| WO (1) | WO2004110486A1 (es) |
| ZA (1) | ZA200509907B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006206851B2 (en) | 2005-01-18 | 2010-12-16 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Mycobacteria with mannose cap-deficient lipoarabinomannan |
| AR059972A1 (es) * | 2006-03-22 | 2008-05-14 | Solvay Pharm Bv | Administracion intranasal o inhalacional de virosomas |
| TWI397419B (zh) * | 2006-03-22 | 2013-06-01 | Abbott Biologicals Bv | 病毒顆粒的鼻內或吸入給藥 |
| US8535683B2 (en) | 2006-03-22 | 2013-09-17 | Abbott Biologicals B.V. | Intranasal or inhalational administration of virosomes |
| US8916164B2 (en) * | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| EP2058002A1 (en) | 2007-10-31 | 2009-05-13 | Bestewil Holding B.V. | Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine |
| EA025275B1 (ru) | 2009-02-06 | 2016-12-30 | Майметикс Корпорейшн | Способ, терапевтическая композиция, вакцинная комбинация и набор для терапевтического или профилактического лечения вич |
| KR101756202B1 (ko) | 2009-02-06 | 2017-07-10 | 마이메틱스 코포레이션 | 신규한 ｇｐ41 항원 |
| EP2549990A1 (en) * | 2010-03-23 | 2013-01-30 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| WO2011128720A1 (en) | 2010-04-14 | 2011-10-20 | Mymetics Corporation | Trans-activator of transcription protein |
| CN103179977B (zh) | 2010-08-27 | 2016-10-26 | 潘塔希生物科学股份有限公司 | 治疗前列腺癌的免疫治疗方法 |
| US20130259928A1 (en) * | 2010-09-30 | 2013-10-03 | Franvax S.R.L. | Generation of virosome particles |
| RU2440140C1 (ru) * | 2010-12-09 | 2012-01-20 | Иосиф Григорьевич Атабеков | Иммуногенная композиция, содержащая чужеродные антигены на поверхности сферических носителей, полученных при термической денатурации спиральных вирусов |
| RU2441667C1 (ru) * | 2010-12-09 | 2012-02-10 | Иосиф Григорьевич Атабеков | Новый тип частиц-носителей (платформ) для получения активных комплексов |
| EP3016679B1 (en) * | 2013-07-02 | 2019-03-27 | Janssen Vaccines & Prevention B.V. | Method for preparing virosomes |
| WO2016039620A2 (en) | 2014-09-12 | 2016-03-17 | Bestewil Holding B.V. | Respiratory syncytial virus virosomes |
| CA2960948C (en) | 2014-09-12 | 2023-04-04 | Bestewil Holding B.V. | Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby |
| WO2016080830A2 (en) | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
| US11819542B2 (en) | 2017-10-31 | 2023-11-21 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating lung cancer by administering a polypeptide comprising an epitope of hZP3 |
| WO2020048924A1 (en) | 2018-09-03 | 2020-03-12 | Laboratoire Hra-Pharma | Zp3 fragments in immunotherapy of ovarian cancer |
| US11523988B2 (en) | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
| US20200188511A1 (en) | 2018-12-12 | 2020-06-18 | Anergis S.A. | Methods of improving efficacy of allergy vaccines |
| WO2021207303A1 (en) * | 2020-04-07 | 2021-10-14 | Alsatech, Inc. | Immune stimulation against coronavirus infections |
| EP4419122A1 (en) | 2021-10-19 | 2024-08-28 | Sciencemed Spólka Z Ograniczona Odpowiedzialnoscia | Male contraception |
| WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
| CN120076824A (zh) * | 2022-10-25 | 2025-05-30 | 宁波明亦生物科技有限公司 | 质膜透化灭活口服疫苗 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4542212A (en) * | 1975-10-14 | 1985-09-17 | Institut Pasteur | Phosphorylated 3-glyceryl-esters of glucose |
| JPS5929931B2 (ja) * | 1980-12-09 | 1984-07-24 | オムロン株式会社 | 安全スイツチ |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| JPH0688911B2 (ja) | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | インフルエンザワクチン及びその製造方法 |
| ATE71303T1 (de) | 1986-01-14 | 1992-01-15 | Nederlanden Staat | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
| NZ224422A (en) | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
| NZ240369A (en) | 1990-10-30 | 1993-09-27 | Daiichi Seiyaku Co | Muramyl dipeptide derivatives and vaccine compositions |
| DE69229703T2 (de) | 1991-05-08 | 2000-04-27 | Schweiz Serum & Impfinst | Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe |
| US20030113347A1 (en) * | 1991-05-08 | 2003-06-19 | Schweiz. Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| US5879685A (en) * | 1991-05-08 | 1999-03-09 | Schweiz, Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| US5936076A (en) * | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| US6417326B1 (en) * | 1996-04-11 | 2002-07-09 | The University Of British Columbia | Fusogenic liposomes |
| US6743900B2 (en) * | 2000-02-15 | 2004-06-01 | Id Biomedical Corporation Of Quebec | Proteosome influenza vaccine |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| US7491395B2 (en) * | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| AU2003296592A1 (en) * | 2002-11-20 | 2004-06-15 | Crucell Holland B.V. | Antigen-complexes |
-
2004
- 2004-06-16 AR ARP040102097A patent/AR056245A1/es unknown
- 2004-06-16 TW TW093117276A patent/TWI329130B/zh not_active IP Right Cessation
- 2004-06-18 ES ES10180937.4T patent/ES2536689T3/es not_active Expired - Lifetime
- 2004-06-18 WO PCT/NL2004/000437 patent/WO2004110486A1/en not_active Ceased
- 2004-06-18 CA CA2527735A patent/CA2527735C/en not_active Expired - Lifetime
- 2004-06-18 JP JP2006516989A patent/JP4685005B2/ja not_active Expired - Fee Related
- 2004-06-18 MX MXPA05013929A patent/MXPA05013929A/es active IP Right Grant
- 2004-06-18 DK DK04748669.1T patent/DK1633395T3/da active
- 2004-06-18 CN CNB2004800167589A patent/CN100556454C/zh not_active Expired - Fee Related
- 2004-06-18 PL PL04748669T patent/PL1633395T3/pl unknown
- 2004-06-18 DK DK10180937.4T patent/DK2368576T3/en active
- 2004-06-18 AU AU2004246974A patent/AU2004246974B2/en not_active Ceased
- 2004-06-18 EP EP10180937.4A patent/EP2368576B1/en not_active Expired - Lifetime
- 2004-06-18 EP EP04748669A patent/EP1633395B1/en not_active Expired - Lifetime
- 2004-06-18 BR BRPI0411519-8A patent/BRPI0411519A/pt not_active Application Discontinuation
- 2004-06-18 US US10/560,594 patent/US7618641B2/en not_active Expired - Lifetime
- 2004-06-18 PL PL10180937T patent/PL2368576T3/pl unknown
- 2004-06-18 UA UAA200512191A patent/UA87269C2/ru unknown
- 2004-06-18 KR KR1020057024393A patent/KR101225199B1/ko not_active Expired - Fee Related
- 2004-06-18 RU RU2006101394/15A patent/RU2348428C2/ru active
- 2004-06-18 ES ES04748669T patent/ES2390454T3/es not_active Expired - Lifetime
-
2005
- 2005-12-06 ZA ZA200509907A patent/ZA200509907B/xx unknown
- 2005-12-14 IL IL172584A patent/IL172584A/en unknown
- 2005-12-14 NO NO20055934A patent/NO20055934L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056245A1 (es) | Membranas virales reconstituidas funcionales que contienen un coadyuvante | |
| Kuate et al. | Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies | |
| CL2020000428A1 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana. | |
| EA201391467A1 (ru) | Липосомные композиции | |
| JP2016519933A5 (es) | ||
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| EA200900784A1 (ru) | Вакцины, включающие антиген из четырех штаммов вируса гриппа | |
| ES2190799T3 (es) | Inmunogenos peptidicos para vacunacion y tratamiento de la alergia. | |
| AR061894A1 (es) | Vacunas para malaria | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| WO2007044731A3 (en) | Recombinant proteins from filoviruses and their use | |
| UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
| MX2021012994A (es) | Administracion heterologa de vacunas tau. | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| MY188083A (en) | Recombinant proteins and their therapeutic uses | |
| NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| WO2007008070A3 (en) | ADJUVATION THROUGH CROSS-β STRUCTURE | |
| MX2018010836A (es) | Conformeros abiertos hla-b57. | |
| Song et al. | Pylipid: a Python toolkit for analysis of lipid-protein interactions from MD simulations | |
| WO2006071896A3 (en) | Epitope-based sars vaccine | |
| EP1439856A4 (en) | RECOMBINANT TOLLWOOD VACCINES AND METHOD FOR THEIR PREPARATION AND USE | |
| MX2021007074A (es) | Péptidos basados en laberintina para inmunoterapias contra el cáncer y su uso. | |
| Arastoo et al. | Phase Partitioning of influenza Virus Neuraminidase in a Model Membrane | |
| Rodriguez | Studying the biology of, and developing countermeasures to, a tick-transmitted hemorrhagic fever virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |